A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer

James J. Harding(Memorial Sloan Kettering Cancer Center), Helen Morement(CRUK Lung Cancer Centre of Excellence), Mohamedtaki Abdulaziz Tejani(AdventHealth Orlando), Hui‐Chuan Sun(Fudan University), Myung Ah Lee(The Catholic University of Korea Seoul St. Mary's Hospital), Lequn Bao(Hubei Cancer Hospital), Melinda Bachini(Cholangiocarcinoma Foundation), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Do‐Youn Oh(Seoul National University Hospital), Emerson Y. Chen(Oregon Health & Science University), Lisa Boyken(Zymeworks (Canada)), Harpreet Wasan(Hammersmith Hospital), Jean‐Philippe Metges(Centre Hospitalier Régional Universitaire de Brest), Stacie Lindsey(Cholangiocarcinoma Foundation), Teresa Macarulla(Vall d'Hebron Hospital Universitari), John Bridgewater(University College London Hospitals NHS Foundation Trust), Jiafang Ma(BeiGene (China)), Shubham Pant(The University of Texas MD Anderson Cancer Center), Michel Ducreux(Université Paris-Saclay), Dong Uk Kim(Pusan National University Hospital), Jin Won Kim(Seoul National University Bundang Hospital), Jia Fan(Nanjing Tech University), Yuanyuan Bao(BeiGene (China)), Hye Jin Choi(Yonsei University), Heung-Moon Chang(Asan Medical Center), Phillip M. Garfin(Zymeworks (Canada)), Feng Xie(Chinese People's Liberation Army)
Future Oncology
August 8, 2024
Cited by 4


Related Papers